Agilon Health (NYSE:AGL - Get Free Report) had its price objective dropped by equities researchers at Barclays from $3.00 to $1.50 in a research note issued on Wednesday,Benzinga reports. The firm presently has an "underweight" rating on the stock. Barclays's price target would indicate a potential upside of 72.04% from the stock's current price.
A number of other equities analysts have also weighed in on the stock. Robert W. Baird dropped their target price on shares of Agilon Health from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Tuesday, April 15th. Evercore ISI decreased their price target on shares of Agilon Health from $5.00 to $3.00 and set an "in-line" rating on the stock in a research note on Wednesday, July 9th. Citigroup raised shares of Agilon Health from a "neutral" rating to a "buy" rating and upped their price target for the company from $3.25 to $5.00 in a research note on Friday, April 25th. Cowen reaffirmed a "hold" rating on shares of Agilon Health in a research note on Tuesday, April 15th. Finally, Wells Fargo & Company decreased their price target on shares of Agilon Health from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $4.08.
View Our Latest Research Report on AGL
Agilon Health Price Performance
Shares of NYSE:AGL traded down $0.00 during midday trading on Wednesday, reaching $0.87. 30,405,277 shares of the company were exchanged, compared to its average volume of 17,026,470. The business's fifty day moving average is $2.08 and its two-hundred day moving average is $3.15. Agilon Health has a one year low of $0.71 and a one year high of $6.08.
Agilon Health (NYSE:AGL - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.14). Agilon Health had a negative return on equity of 66.76% and a negative net margin of 5.35%. The company had revenue of $1.39 billion for the quarter, compared to the consensus estimate of $1.47 billion. During the same quarter in the prior year, the company posted ($0.07) EPS. Agilon Health's revenue was down 5.9% compared to the same quarter last year. As a group, sell-side analysts expect that Agilon Health will post -0.59 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Agilon Health
Several hedge funds and other institutional investors have recently made changes to their positions in AGL. Humankind Investments LLC purchased a new stake in shares of Agilon Health in the fourth quarter valued at $30,000. Raymond James Financial Inc. purchased a new stake in shares of Agilon Health in the fourth quarter valued at $33,000. Cerity Partners LLC purchased a new stake in shares of Agilon Health in the fourth quarter valued at $34,000. 111 Capital purchased a new position in Agilon Health in the 2nd quarter worth about $36,000. Finally, Nisa Investment Advisors LLC increased its stake in Agilon Health by 244.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 9,553 shares of the company's stock worth $41,000 after buying an additional 6,783 shares during the period.
Agilon Health Company Profile
(
Get Free Report)
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
Featured Stories

Before you consider Agilon Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilon Health wasn't on the list.
While Agilon Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.